Butyrolactone 3
Based on 13 publication(s) in Google Scholar
Butyrolactone 3 (MB-3) is a specifical small-molecule inhibitor of the histone acetyltransferase Gcn5 (IC50=100 μM), which has a high affinity to the Gcn5 enzyme comparable to that of its natural substrate, histone H3. Butyrolactone 3 shows weak inhibitory on CBP (IC50=0.5 mM). Butyrolactone 3 can be used in studies of cancer, metabolic, autoimmune and neurological diseases.
For research use only. We do not sell to patients.
- Purity: 99.58%
- CAS No.: 778649-18-6
- Formula: C9H12O4
- Molecular Weight:184.19
-
Storage:Powder -20°C, 3 years
* The compound is unstable in solutions, freshly prepared is recommended.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Butyrolactone 3
More- Cancer Discov. 2025 Sep 19. [Abstract]
- Nat Genet. 2024 Apr;56(4):663-674. [Abstract]
- Mol Cell. 2025 Jul 17;85(14):2654-2672.e7. [Abstract]
- Adv Sci (Weinh). 2024 Jul 9:e2406333. [Abstract]
- Pharmacol Res. 2025 Jan 30:107632. [Abstract]
- Cell Death Dis. 2022 Apr 30;13(4):421. [Abstract]
- J Agric Food Chem. 2022 Jan 12;70(1):403-414. [Abstract]
- Liver Int. 2023 Aug;43(8):1729-1740. [Abstract]
- Int Immunopharmacol. 2026 Mar 15:173:116305. [Abstract]
- iScience. 2026 Apr 16;29(5):115805. [Abstract]
- Immunotargets Ther. 2025 Dec 28:14:1515-1529. [Abstract]
- Neurosci Lett. 2022 Jul 27:784:136742. [Abstract]
- bioRxiv. 2026 Jun 22.
Customer Validation & Images
-
Histological Imaging/Staining
-
Histological Imaging/Staining
-
Histological Imaging/Staining
-
IF
-
Bio/Physico-chemical Assay
Biological Activity
|
GCN5 100 μM (IC50) |
Butyrolactone 3 (50, 100, 200 μM, 16 h) can reduce acetylation of Gcn5 and induce degradation of E2A-PBX1[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:RCH-ACV
-
Concentration:50, 100, 200 μM
-
Incubation Time:16 h
-
Result:Decreased the protein levels of E2A-PBX1 and E2A in a dose-dependent manner.
Reduced Wnt16 and GCN5 protein levels.
Chemical Information
-
CAS No. 778649-18-6
-
Appearance Solid
-
Molecular Weight 184.19
-
Formula C9H12O4
-
Color White to off-white
-
SMILES
O=C([C@@H](C1=C)[C@@H](CCC)OC1=O)O
-
Synonyms
MB-3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years * The compound is unstable in solutions, freshly prepared is recommended.
Publications (13)
-
Journal Impact Factor
-
Most Recent
-
Cancer Discov
Activation of T cell-intrinsic p53 by acetylation elicits antitumor immunity to boost cancer immunotherapy. [Abstract]2025 Sep 19. PMID: 40970761 -
Nat Genet
MYC activity at enhancers drives prognostic transcriptional programs through an epigenetic switch. [Abstract]2024 Apr;56(4):663-674. PMID: 38454021 -
Mol Cell
Lactylation of XLF promotes non-homologous end-joining repair and chemoresistance in cancer. [Abstract]2025 Jul 17;85(14):2654-2672.e7. PMID: 40680721 -
Adv Sci (Weinh)
Lactylated Apolipoprotein C-II Induces Immunotherapy Resistance by Promoting Extracellular Lipolysis. [Abstract]2024 Jul 9:e2406333. PMID: 38981044
Butyrolactone 3 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Jul 9:e2406333. [Abstract]
H1299 cells were treated with Lactate (20 mM), A-485, KAT8-IN-1 (300 µM), NU9056 (2 µM), Butyrolactone 3 (MB-3, 300 µM), or Gln-AMS (10 µM) for 14 h. Quantitative analysis of extracellular FFAs was conducted post-treatment.
-
Pharmacol Res
Histone lysine crotonylation accelerates ACSL4-mediated ferroptosis of keratinocytes via modulating autophagy in diabetic wound healing. [Abstract]2025 Jan 30:107632. PMID: 39892437 -
Cell Death Dis
GCN5-mediated regulation of pathological cardiac hypertrophy via activation of the TAK1-JNK/p38 signaling pathway. [Abstract]2022 Apr 30;13(4):421. PMID: 35490166
Butyrolactone 3 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2022 Apr 30;13(4):421. [Abstract]
Effects of GCN5 inhibitor Butyrolactone 3 on binding of TAK1 with TAB1 and TAB2 in NRCMs under PE treatment.
-
J Agric Food Chem
Antimicrobial Peptide BCp12 Inhibits Staphylococcus aureus Growth by Altering Lysine Malonylation Levels in the Arginine Synthesis Pathway. [Abstract]2022 Jan 12;70(1):403-414. PMID: 34942069 -
Liver Int
Inhibition of ACSS2 attenuates alcoholic liver steatosis via epigenetically regulating de novo lipogenesis. [Abstract]2023 Aug;43(8):1729-1740. PMID: 37183518 -
Int Immunopharmacol
α-Methylene-γ-butyrolactone 3 inhibits the activation of NLRP3 inflammasome in sepsis by blocking both the priming and inflammasome assembly. [Abstract]2026 Mar 15:173:116305. PMID: 41628514 -
iScience
Epigenome regulators imbue a single eukaryotic promoter with diverse gene expression dynamics. [Abstract]2026 Apr 16;29(5):115805. PMID: 42111206 -
Immunotargets Ther
Inhibitors of KAT2A Alleviate the Progression of AKI by Alleviating Macrophage Ferritinophagy. [Abstract]2025 Dec 28:14:1515-1529. PMID: 41476772
Butyrolactone 3 purchased from MedChemExpress. Usage Cited in: Immunotargets Ther. 2025 Dec 28:14:1515-1529. [Abstract]
HE staining image of r renal tissues in sham-treated and I/R-treated C57BL/6 mice in the presence or absence of Butyrolactone 3 (10 mg/kg, iv).
Butyrolactone 3 purchased from MedChemExpress. Usage Cited in: Immunotargets Ther. 2025 Dec 28:14:1515-1529. [Abstract]
PAS staining image of kidney from sham-treated and I/R-treated C57BL/6 mice in the presence or absence of Butyrolactone 3 (10 mg/kg, iv).
Butyrolactone 3 purchased from MedChemExpress. Usage Cited in: Immunotargets Ther. 2025 Dec 28:14:1515-1529. [Abstract]
Masson’s trichrome staining in the renal cortex from sham-treated and I/R-treated C57BL/6 mice in the presence or absence of Butyrolactone 3 (10 mg/kg, iv)
Butyrolactone 3 purchased from MedChemExpress. Usage Cited in: Immunotargets Ther. 2025 Dec 28:14:1515-1529. [Abstract]
The expression of KAT2A and F4/80 proteins in kidney tissue of IR-AKI mice was up-regulated by uIRI treatment, and significantly decreased after Butyrolactone 3 (10 mg/kg, iv) treatment.
-
Neurosci Lett
2022 Jul 27:784:136742. PMID: 35716963 -
Solvent & Solubility
DMSO : 100 mg/mL (542.92 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (11.29 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (11.29 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * The compound is unstable in solutions, freshly prepared is recommended.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
Handling Instructions (2659 KB)
References
[1]. Biel M,et al. Design, synthesis, and biological evaluation of a small-molecule inhibitor of the histone acetyltransferase Gcn5.Angew Chem Int Ed Engl. 2004 Jul 26;43(30):3974-6 [Content Brief]
[2]. Haque ME, et al. The GCN5: its biological functions and therapeutic potentials. Clin Sci (Lond). 2021 Jan 15;135(1):231-257. [Content Brief]
[3]. Holmlund T, et al. GCN5 acetylates and regulates the stability of the oncoprotein E2A-PBX1 in acute lymphoblastic leukemia. Leukemia. 2013 Mar;27(3):578-85. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 5.4292 mL | 27.1459 mL | 54.2918 mL | 135.7294 mL |
| 5 mM | 1.0858 mL | 5.4292 mL | 10.8584 mL | 27.1459 mL | |
| 10 mM | 0.5429 mL | 2.7146 mL | 5.4292 mL | 13.5729 mL | |
| 15 mM | 0.3619 mL | 1.8097 mL | 3.6195 mL | 9.0486 mL | |
| 20 mM | 0.2715 mL | 1.3573 mL | 2.7146 mL | 6.7865 mL | |
| 25 mM | 0.2172 mL | 1.0858 mL | 2.1717 mL | 5.4292 mL | |
| 30 mM | 0.1810 mL | 0.9049 mL | 1.8097 mL | 4.5243 mL | |
| 40 mM | 0.1357 mL | 0.6786 mL | 1.3573 mL | 3.3932 mL | |
| 50 mM | 0.1086 mL | 0.5429 mL | 1.0858 mL | 2.7146 mL | |
| 60 mM | 0.0905 mL | 0.4524 mL | 0.9049 mL | 2.2622 mL | |
| 80 mM | 0.0679 mL | 0.3393 mL | 0.6786 mL | 1.6966 mL | |
| 100 mM | 0.0543 mL | 0.2715 mL | 0.5429 mL | 1.3573 mL |
Butyrolactone 3 Related Classifications
HY-129039 Related Classifications
Powered by Bioz